ECM
TRIL

Endurant Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Endurant Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-600,788
Closed -$7.02M – 72
2021
Q2 		$5.83M Buy
600,788
+122,414
+26% +$1.15M 1.6% 24
2021
Q1 		$5.14M Sell
478,374
-177,367
-27% -$2.19M 1.34% 29
2020
Q4 		$9.65M Buy
655,741
+283,340
+76% +$4.09M 3.48% 4
2020
Q3 		$5.29M Sell
372,401
-305,422
-45% -$3.05M 1.57% 20
2020
Q2 		$5.48M Buy
677,823
+200,119
+42% +$1.24M 0.3% 19
2020
Q1 		$1.93M Buy
+477,704
New +$1.81M 0.87% 30
2016
Q4 		– Sell
-24,400
Closed -$361K – 99
2016
Q3 		$361K Sell
24,400
-2,900
-11% -$33.4K 0.13% 80
2016
Q2 		$245K Buy
27,300
+14,800
+118% +$154K 0.08% 84
2016
Q1 		$116K Hold
12,500
– – 0.04% 86
2015
Q4 		$158K Buy
+12,500
New +$174K 0.05% 77

Other funds holding TRIL

Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Endurant Capital Management's TRIL Position: Q3 2021 in Review

Endurant Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 600,788 shares — an estimated $7.02M sold.

Endurant Capital Management first reported a position in TRIL in Q4 2015 and held it in 10 quarters. The position peaked at $9.65M in Q4 2020. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Endurant Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Endurant Capital Management sold 600,788 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $7.02M.
  • Endurant Capital Management first reported a position in Trillium Therapeutics Inc. in Q4 2015 and held it in 10 quarters.
  • Endurant Capital Management's Trillium Therapeutics Inc. position peaked at $9.65M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Endurant Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.